SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (21550)5/29/1998 8:23:00 AM
From: Biotech Jim  Read Replies (5) of 32384
 
Any news on the cytokine receptor small molecule molecule agonist front? Have you spoken with IR recently about this. I have been doing a lot of reading in the cytokine agonist area and I think this is close to impossible. I'm also curious about the issue of species selectivity of the compound(s), as the agonist binding pockets should be largely similar. Unless, of course, as for certain other peptidergic G-protein coupled receptors there are distinct receptor protein residues that are only directly interacting with the small molecule and not with the natural agonist ligand. Also, Henry, do you know whether there are small molecule antagonists that block natural agonist binding? I find it curious that Robinson did not say mauch about the small molecule program at the annual meeting. On the other hand, he was quite suberb on his discussion of the various extant programs, I am happy to say.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News